No deadline noted
Patient Engagement Navigator
Health Technology Assessment
Innovative, collaborative and results-driven.
These key words will be your guide as you join a dedicated team committed to patient engagement, transparency and collaboration. Working closely with the Canadian patient community, as well as a growing network of stakeholders and partners, the Health Technology Assessment (HTA) Patient Engagement Navigator will play a key role in helping to build a sustainable, multi-faceted HTA Patient Engagement Model in Canada.
The HTA Patient Engagement Navigator role is a joint initiative of the Canadian Cancer Action Network (CCAN) and the pan-Canadian Oncology Drug Review (pCODR), a program of the Canadian Agency for Drugs and Technologies in Health (CADTH). The HTA Patient Engagement Navigator will serve as a live support for the patient community in order to further enhance patient community involvement in the health technology assessment of new cancer drugs in Canada. This is a temporary full-time position to end March 31, 2017 with the possibility of an extension.
Overview of Role
The HTA Patient Engagement Navigator, reporting to the CEO of CCAN, is accountable to a multi-disciplinary Project Advisory Committee comprised of key stakeholders and partners. The HTA Patient Engagement Navigator will play a key role in enhancing awareness and promoting transparency for Canadian HTA processes. The HTA Patient Engagement Navigator will serve as a knowledge broker linking the Canadian cancer patient community to the HTA drug review process prior to a manufacturer or tumour group making a submission to pCODR for review, as well as after funding recommendations are issued by pCODR’s Expert Review Committee. Further, the HTA Patient Engagement Navigator will research publically available information required to support the Cancer Drug Information Pipeline, as well as contribute to the evaluation on the effectiveness of the Pipeline by monitoring its use and performance and identifying areas for improvement. Based in a downtown Toronto office, the HTA Patient Engagement Navigator will contribute to the longer-term vision of enhanced patient community awareness and engagement, as well as high quality information and tools. As a result, the integration of patient-based values in the cancer drug review processes will continue to strengthen.
- Build a high-performing, sustainable HTA Patient Engagement Model that includes the tools, resources, information and support needed to further optimize patient engagement in the patient evidence submission process, and to evaluate and measure advancements in engagement.
- Be responsible for supporting patient community engagement, developing and introducing new resources and delivering results on time and within budget.
- Be accountable for driving collaborative efforts with the patient community, project partners and key stakeholders in order to further strengthen the inclusion of patient-based values in HTA.
- Provide support to members of the patient community seeking to participate in the HTA patient evidence submission process.
- Serve as a knowledge broker and establish/maintain relationships with the patient community in order to promote engagement.
- Represent CCAN as an active member on the CADTH Patient Community Liaison Forum, and serve as a liaison with the broader Canadian patient community.
- Identify and record new drugs coming to Canada in order to populate and maintain the Cancer Drug Information Pipeline.
- Develop and monitor progress of the project lifecycle.
- Contribute options, in consultation with project team members and other experts as applicable, in the development of future policy and strategy development to enhance patient community involvement in the HTA processes.
- Other related duties as required.
- Master’s degree (asset) or equivalent mixture of education and experience, in a relevant field such as public health, health policy or health sciences.
- Background and strong work experience in the Canadian healthcare sector (preferably in cancer control, public health and administration or health economy) combined with familiarity and/or an understanding of the CADTH/pCODR program
- A minimum of 5 years demonstrated experience in healthcare-related patient engagement and public participation including planning, capacity building, performance measurement, as well as implementation and evaluation strategies.
- Understanding of patient and public involvement policies, principles and techniques (such as IAP2), with a proven ability to translate into practice.
- Experience in information dissemination and demonstrated ability to apply best practices in knowledge mobilization, as well as an understanding of evidence-informed practices and decision making.
- Ability to develop and/or inform the development, promotion and evaluation of knowledge products using feedback from knowledge users, key stakeholders and content experts.
- A self-starter with excellent research and project management skills, and a proven ability to meet multiple priorities amidst important and competing timelines.
- An experienced communicator with superior written and oral communication and strong interpersonal skills.
Apply in confidence quoting FILE NO: HTA022016: email@example.com
We are pleased to provide a competitive salary rate as part of an attractive compensation package for this role. We thank all applicants for their interest in this opportunity however only those selected for an interview will be contacted.
Founded in 2001, CCAN is a national patient-centred umbrella organization working closely with patient advocacy groups and other key cancer control stakeholders across Canada. With a membership expansion rate of more than 200% in the last three years, the organization engages 114 diverse member organizations to embed an informed and coordinated patient and caregiver perspective in defined areas of priority or interest to the community.
CADTH’s pan-Canadian Oncology Drug Review is an evidence-based, cancer drug review process designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness and patient perspectives in order to provide funding recommendations to Provinces and Territories and cancer agencies.
The HTA Patient Engagement Navigator initiative is funded by the Canadian Partnership Against Cancer with in-kind funding provided by CADTH and CCAN.